Pictet Asset Management (Switzerland)’s Amicus Therapeutics FOLD Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$119M	Sell	9,442,588 -542,313	-5%	-$6.44M	0.14%	180
2023 Q1	$111M	Buy	9,984,901 +1,553,949	+18%	+$19.2M	0.14%	188
2022 Q4	$103M	Buy	8,430,952 +4,945,650	+142%	+$55.7M	0.15%	188
2022 Q3	$36.4M	Buy	3,485,302 +2,842,220	+442%	+$31.7M	0.05%	324
2022 Q2	$6.91M	Buy	643,082 +229,613	+56%	+$1.89M	0.01%	687
2022 Q1	$3.92M	Sell	413,469 -8,348	-2%	-$78.3K	﹤0.01%	859
2021 Q4	$4.87M	Buy	421,817 +28,773	+7%	+$321K	﹤0.01%	840
2021 Q3	$3.75M	Buy	+393,044	New	+$4.02M	﹤0.01%	899

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s FOLD Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Amicus Therapeutics (FOLD) stake by 5.4% in Q2 2023, selling an estimated $6.44M and leaving 9,442,588 shares worth $119M. The position accounts for 0.14% of the portfolio, ranked #180.

Pictet Asset Management (Switzerland) first reported a position in FOLD in Q3 2021 and has held it in 8 quarters since. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

Pictet Asset Management (Switzerland) held 9,442,588 shares of Amicus Therapeutics worth $119M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 542,313 Amicus Therapeutics shares in Q2 2023, an estimated $6.44M.
Amicus Therapeutics made up 0.14% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #180 holding.
Pictet Asset Management (Switzerland) first reported a position in Amicus Therapeutics in Q3 2021 and has held it in 8 quarters since.
216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.